United States · 
What does Atlas Venture invest in?
Atlas Venture invests most often at Series A and Series B (53% of the rounds on record), in sectors such as In Vitro Diagnostics, Pharma and Drugs.
Atlas Venture highlights
- 01
11 cheques in the last 12 months
- 02
Mostly Series A and Series B: 53% of its rounds
- 03
Sole investor in 24 rounds, median $3.2M
- 04
55 exits from the portfolio
What they do
We build breakthrough biotechnology companies.From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- Up to $50M as they say
- Stages
- SeedSeries ASeries BGrowthPre-IPO
- Sectors
- In Vitro DiagnosticsPharmaDrugs
- Based in
- Cambridge, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first492 appearances
- 2026
6 rounds
- Oct
- Sept
- Jun
- Mar
- Jan
- Jan
- 2025
9 rounds
- Dec
- Dec
- Nov
- Nov
- Nov
- Oct
- Jul
- May
- Jan
- 2024
13 rounds
- Dec
- Nov
- Oct
- Oct
- Oct
- Aug
- Aug
- Jun
- May
- Mar
- Jan
- Jan
- Jan
- 2023
9 rounds
- Oct
- Oct
- Sept
- Sept
- Jun
- May
- Mar
- Mar
- Feb
- 2022
6 rounds
- Oct
- Sept
- Feb
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration13 named
BLBruce Lee BoothMember of the General Partner and the GPLLCiFiling they signed
DGDavid GrayzelMember of the General Partner and the GPLLCiFiling they signed
FVFrancis Victor CastellucciGeneral Counsel, SecretaryiForm ADV
GMGladstone MichaelMemberiForm ADV
JPJason Paul RhodesMember of the General Partner and the GPLLCiFiling they signed
JBJean-Francois Bernard FormelaMember of the General Partner and the GPLLCiFiling they signed
JLJeffrey Lyle FagnanShareholder, Director, Vice PresidentiForm ADV
JKJon KarlenManaging Director of the ManageriFiling they signed
KBKevin BittermanMember of the sole member of the GPLLCiFiling they signed
MGMichael GladstoneMember of the sole member of the GPLLCiFiling they signed
OCOmmer ChohanCFOiForm ADV
PBPeter BarrettMember of the General Partner and the GPLLCiFiling they signed
TLTravis Leigh MacinnesChief Financial Officer and TreasureriForm ADV
We also hold 48 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$5.0Bgross assets of its funds, 2 advisers combinedOct 2026
Exemptreporting adviserventure or small private funds
- Legal name
- Atlas Venture Advisors, Inc.
- SEC number
- CRD 162935
What they claim to have backed
From their own portfolio page (on their website)
22 of 36 we have independently watched raise
AavantgardebioComanchebiopharmaDiscmedicineEthyrealbioGenerationbioHorizontherapeuticsHotspottheraIfmtheraIkenaoncologyJnjJudoKaileraKinasettherapeuticsKorrobioMarianaoncologyMorphosysNchromabioQ32bioRenasantbioReplimuneSperotherapeuticsThirdharmonicbioAlnylamCogentbioDayonebioExelixisF-starLifeSciVCLifordiMerckRectifypharmaShow + TellTraceneuroTrianabioTriveniVigilneuro
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed55 in all
Chronos Mobile TechnologiesBought by Life360UndisclosedAug 2015
AllclassesBought by NoodleUndisclosedJul 2015
DailymotionBought by VivendiUndisclosedJun 2015
Objective LogisticsBought by Bit9UndisclosedJun 2015
SnapguideBought by Brit + CoUndisclosedJun 2015
RocketmilesBought by Priceline$20MFeb 2015
Mortar DataBought by DatadogUndisclosedFeb 2015
Annovation BioPharmaBought by The Medicines CompanyUndisclosedFeb 2015
3V Transaction ServicesBought by SafeChargeUndisclosedDec 2014
UbersenseBought by HudlUndisclosedSept 2014
GrabCADBought by Stratasys$100MSept 2014
TimbreBought by SeatwaveUndisclosedJun 2014
docTrackrBought by Intralinks$10MApr 2014
COLOURloversBought by AutodeskUndisclosedMar 2014
CoStim PharmaceuticalsBought by NovartisUndisclosedFeb 2014
ZinwaveBought by McWaneUndisclosedFeb 2014
StromedixBought by Biogen Idec$750MFeb 2014
The latest 20 here. An exit counts when it came after the firm's first round in the company. From historical deal records.